Emerging peptide therapies are disrupting the landscape of metabolic disease treatment. Among these groundbreaking advancements, semaglutide and tirzepatide stand out as effective agents with remarkable therapeutic potential. These glucagon-like peptide-1 (GLP-1) receptor agonists demonstrate unique mechanisms of action that address multiple facets